Covid-2019 - 2021-09-30

In "Recommended Reading," possibly a breakthrough from Merck -- the oddly named Molnupiravir, a post-infection therapeutic that, in trials, reduces hospitalizations from Covid by 50%. Two fearless forecasts. First, the monomaniacal vaccine fanatics will dump on it because successful treatments keep people from getting vaccinated, supposedly. Second, when this starts getting advertised on TV, you'll hear "Don't take Molnupiravir if you are allergic to Molnupiravir."